1. Home
  2. DSGN vs BYND Comparison

DSGN vs BYND Comparison

Compare DSGN & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • BYND
  • Stock Information
  • Founded
  • DSGN 2017
  • BYND 2009
  • Country
  • DSGN United States
  • BYND United States
  • Employees
  • DSGN N/A
  • BYND N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • BYND Packaged Foods
  • Sector
  • DSGN Health Care
  • BYND Consumer Staples
  • Exchange
  • DSGN Nasdaq
  • BYND Nasdaq
  • Market Cap
  • DSGN 208.9M
  • BYND 214.6M
  • IPO Year
  • DSGN 2021
  • BYND 2019
  • Fundamental
  • Price
  • DSGN $6.54
  • BYND $2.20
  • Analyst Decision
  • DSGN
  • BYND Sell
  • Analyst Count
  • DSGN 0
  • BYND 5
  • Target Price
  • DSGN N/A
  • BYND $96.50
  • AVG Volume (30 Days)
  • DSGN 173.8K
  • BYND 8.1M
  • Earning Date
  • DSGN 11-06-2025
  • BYND 11-05-2025
  • Dividend Yield
  • DSGN N/A
  • BYND N/A
  • EPS Growth
  • DSGN N/A
  • BYND N/A
  • EPS
  • DSGN N/A
  • BYND N/A
  • Revenue
  • DSGN N/A
  • BYND $301,353,000.00
  • Revenue This Year
  • DSGN N/A
  • BYND N/A
  • Revenue Next Year
  • DSGN N/A
  • BYND $0.73
  • P/E Ratio
  • DSGN N/A
  • BYND N/A
  • Revenue Growth
  • DSGN N/A
  • BYND N/A
  • 52 Week Low
  • DSGN $2.60
  • BYND $1.23
  • 52 Week High
  • DSGN $7.77
  • BYND $6.81
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 54.51
  • BYND 41.52
  • Support Level
  • DSGN $5.88
  • BYND $1.24
  • Resistance Level
  • DSGN $7.59
  • BYND $2.65
  • Average True Range (ATR)
  • DSGN 0.51
  • BYND 0.27
  • MACD
  • DSGN -0.06
  • BYND -0.02
  • Stochastic Oscillator
  • DSGN 37.42
  • BYND 54.42

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

Share on Social Networks: